- GAAP EPS increases 35% to record $1.11 - Non-GAAP Economic EPS increases 15% to record $1.17 - Estimated Remaining Collections increase to record $5.1 billion
- Encore deploys $336 million worldwide, $174 million in core U.S. market - Encore completes Atlantic Credit & Finance servicing platform and portfolio acquisition SAN DIEGO , Nov.
EnLink Midstream Partners, LP (NYSE: ENLK) (the Partnership) today
announced the pricing of $100.0 million aggregate principal amount of
its 4.400% senior notes due 2024 (the “2024 Notes”) and $300.0 million
aggregate principal amount of its 5.050% senior notes due 2045, at
prices to the public of 104.007% and 99.452%, respectively, of their
- Third Quarter 2014 Net Revenue and Consolidated Adjusted EBITDA Increase 8% and 5% Respectively - - Free Cash Flow Increases 26% - - Establishes New Digital Media Segment -
- Repurchases 0.8 Million Shares in the Third Quarter - SANTA MONICA, Calif.
Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company
creating innovative personalized therapeutics for patients with
genetically defined cancers, today announced third quarter 2014
operating and financial results and confirmed 2014 guidance.
Epizyme, Inc., a clinical stage biopharmaceutical company creating
innovative personalized therapeutics for patients with genetically
defined cancers, today announced the publication on the website of the
American Society of Hematology (ASH) of an abstract entitled “The DOT1L
Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients
with MLL-Rearranged Leukemia”. The abstract contains preliminary data
from the Phase 1 trial of EPZ-5676, a potent and selective inhibitor of
the DOT1L histone methyltransferase (HMT). EPZ-5676 is being developed
for the treatment of acute leukemia with alterations in the MLL
gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD).
The Company plans to present updated data from the trial at the 56 th
annual meeting of ASH in San Francisco, Calif.
Erickson Incorporated (NASDAQ:EAC) (“Erickson,” the “Company,” “we,”
“us” and “our”), a leading global provider of aviation services to a
worldwide mix of commercial and government customers and the vertically
integrated manufacturer and operator of the powerful, heavy-lift
helicopter, the Erickson S-64 Aircrane, today announced third quarter
and year to date 2014 financial results.
Eros International Plc (NYSE:EROS) (“Eros”), a leading global company in
the Indian film entertainment industry, announced today that it will
issue a press release to report its results for the fiscal second
quarter 2015 before the market opens on Wednesday, November 12, 2014.
GENEVA, SWITZERLAND--(Marketwired - November 06, 2014) - Etrion Corporation ("Etrion" or the "Company") (TSX: ETX) (OMX: ETX), a solar independent power producer, today released its condensed consolidated interim financial statements and related management's discussion and analysis ("MD&A") for the three and nine months ended September 30, 2014.
Exelixis, Inc. (NASDAQ:EXEL) today announced that the enrollment target
of 650 patients has been reached for METEOR, the company’s phase 3
pivotal trial of cabozantinib in patients with metastatic renal cell
carcinoma (RCC) who have experienced disease progression following
treatment with at least one VEGFR tyrosine kinase inhibitor (TKI).
Top-line efficacy and safety data from METEOR are now expected in the
second quarter of 2015.
MARKHAM, ON--(Marketwired - November 06, 2014) - Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) today reported results for the three and nine months ended September 30, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.